Loading...
The benefit of percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) is controversial. In FAME 2, an extension of the manufacturer-sponsored FAME trial (JW Cardiol Jan 14 2009), investigators have now compared fractional flow reserve (FFR)–guided PCI (with drug-eluting stents) with medical therapy alone in patients with stable CAD and one or more angiographic stenoses. Included were 888 randomized patients with FFR of ≤0.80 in at least one stenosis and 166 patients with FFR >0.80 in all stenoses who were enrolled in a registry. All patients received best medical therapy (according to current guidelines). Mean age at baseline was 64; about three quarters of patients were men, one quarter had diabetes, and about 90…